RecruitingPhase 1NCT07206758

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

A Phase I Study Evaluating the Safety, Efficacy, Pharmacokinetics and Pharmacokinetics of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd

Enrollment

10 participants

Start Date

Nov 12, 2025

Study Type

INTERVENTIONAL

Conditions

Immune Thrombocytopenia

Summary

Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-2173 Injection for people with immune thrombocytopenia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-2173 Injection

SHR-2173 injection treatment

Locations(1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07206758

Related Trials

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

NCT0710456540 locations

A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag

NCT075877231 location

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT0700796236 locations

Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia

NCT076577931 location

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

NCT048004581 location